Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Shareholder Meeting (September 2023)
20 slides from Aarti Drugs's shareholder meeting presentation, Sep 26, 2023
Slide 1: Stock exchange cover letter: Presentation to Shareholders
Ref. No: ADL/SE/2023-24/72 September 26, 2023 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block, Bandra - Kurla Complex, Mumbai – 400 001 Bandra
Slide 2: Aarti Drugs Limited Annual General Meeting
AARTI DRUGS LIMITED Annual General Meeting September 26, 2023
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Aarti Drugs Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Company Overview
ao ny” L Company x Overview
Slide 5: Key Milestones
Key Milestones 2023 Consolidated Revenue Rs. 2,700+ Cr 2017 Pinnacle Life Science Pvt. Ltd. crossed Rs. 100 crores turnover 2020 Crossed Rs. 2,000 Cr 2003 Consolidated Turnover & Rs. 1996 Listed On National Stock 200 Cr Formulations Turnover Amalgamation of Rupal Chemical Exchange of India Limited I
Slide 6: Key Facts & Figures
Key Facts & Figures Largest producer of Nimesulide in the world. 12 4,261 Manufacturing MT/Monthly Facilities Capacity Largest producer of Metronidazole in Largest producer of India Ketoconazole in the world 80+ 1,10,330 Finished Products Sq.m Plant Area Leadership in API One of the leading Manufact
Slide 7: State-of-the-art Integrated manufacturing facilities
State-of-the-art Integrated manufacturing facilities Baddi Pinnacle Plant Formulation Plant WHO-GMP Sarigam-1 WHO-GMP Sarigam-2 WHO-GMP/ COFEPRIS/CEP E-22 W-61 ▪ Australian Government – Department of Health and EUGMP & WHO-GMP Ageing - Therapeutic Goods Administration ▪ EUGMP / WHO-GMP / Japanese Ac
Slide 8: ESG Initiatives
ESG Initiatives Environmental Social Governance • Converted multiple facilities into to Zero • Woman Empowerment: Free Government • The Board has an optimum combination of Liquid Discharge (ZLD) approved and certified vocational course training Executive and Non-Executive directors and • Dual Fired
Slide 9: Diversified geographic presence
Diversified geographic presence Presence in 100+ Countries across Top 10 Countries - Exports 6 Continents ensures Brazil Mexico diversification and risk minimization Pakistan Turkey Europe Indonesia UAE 12% 15% Egypt France FY22 FY23 Asia Switzerland Germany North America Market 54% 51% FY22 FY23 13
Slide 10: Corporate Social Responsibility
Corporate Social Responsibility Donation of Inverter, Water filters, Air coolers Steel cupboards, Table chair sets, Washing Machines, Wooden Medicine Racks, Examination Stools to Coconut Tree Plantation various villages, School Construction 9
Slide 11: Capex to drive the next leg of growth
Capex to drive the next leg of growth Capex of Rs. 600 crores underway [starting from FY22 for the next 4-5 years] Capex plans Phase wise capex will lead to distributed investments Majority of the capex to be funded through internal accruals and minimal debt Brownfield expansion and debottlenecking
Slide 12: Financial Highlights of FY23 and Q1FY24
11 Financial Highlights of FY23 and Q1FY24
Slide 13: FY23 Result Highlights
FY 23 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 13.7% 11.3% 8.2% 6.1% +9% 2,718 341 205 2,500 308 166 FY22 FY23 FY22 FY23 FY22 FY23 1. EBITDA includes other income & excludes exceptional items 13
Slide 14: Q1 FY24 Result Highlights
Q1 FY24 Result Highlights Rs. crores Revenue EBITDA & EBITDA Margin (%) PAT & PAT Margin (%) 10.8% 12.7% 12.8% 5.6% 7.6% 7.3% +6.3% 742 94 56 661 85 622 48 67 35 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 1. EBITDA includes other income & excludes exceptional items 14
Slide 15: FY22 Segmental Break-up
FY22 Segmental Break-up FY22 FY23 11% 10% 4% 5% 80% 82% 3% 5% API Formulation API Formulation Speciality Chemicals Intermediates & Others Speciality Chemicals Intermediates & Others 15
Slide 16: Historical Performance At A Glance
16 Historical Performance At A Glance
Slide 17: Strong Financial Performance
Strong Financial Performance Consolidat ed Revenue (Rs. Crores) EBITDA (Rs. Crores) PAT (Rs. Crores) 2,718 442 280 2,500 2,159 341 308 205 1,808 1,563 263 166 210 141 90 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 EBITDA Margin (%) PAT Margin (%) 20.5% 13.0% 14.6% 13.7
Slide 18: Strong Financial Performance
Strong Financial Performance Consolidated EPS* (in Rs.) Net Worth (in Rs. Crores) Leverage (X) 30.1 1,193 0.9 1,036 22.1 913 18.0 0.6 15.4 653 0.5 0.5 544 0.4 9.6 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 * For EPS, adjusted includes previous year’s figures in propor
Slide 19: Distribution to Shareholders
Distribution to Shareholders (in Rs. Crs) Distribution Policy Distributed ~Rs. 54 Crores as Dividend over last 8 years Distribution: ~21.5% Considering various financial parameters, the Company Distributed ~ Rs. 250 crores in may elect to distribute about form of dividend & buyback of 15% to 30% of
Slide 20: Thank You
Thank You